AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

This is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for liver metastases from metastatic colorectal cancer.

NCT Number	NCT07544784
Lead Sponsor	Fudan University
Conditions	Colorectal Cancer Liver Metastases (CRLM)
Enrollment	73 participants
Start Date	2025-11-04
Primary Completion	2027-12-01 (estimated)
Study Completion	2028-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-22